Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sheryl Knott

Clinical Nurse Specialist Bloomington, IN Nurse Practitioner

NPI 1013587575 CMS profile 11214673

2651 E Discovery Pkwy, Bloomington, IN 47408

Open in the dashboard

General payments

$14,227

633 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheryl Knott of Bloomington, IN is reported in the CMS Open Payments database as having received $14,227 across 633 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Clinical Nurse Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,666 115
2024 General $3,550 162
2023 General $3,736 169
2022 General $3,504 147
2021 General $771 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheryl Knott
  • Clinical Nurse Specialist median
  • Middle half of Clinical Nurse Specialist
  • National median

In program year 2025, general payments to Sheryl Knott were reported at $2,666. Among 490 Clinical Nurse Specialist profiles paid that year, the median was $149 and the middle half received between $61 and $470.

Show as a table
Year Sheryl Knott Clinical Nurse Specialist median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $771 $132 $42–$386 $132
2022 $3,504 $140 $55–$364 $149
2023 $3,736 $145 $50–$403 $160
2024 $3,550 $145 $55–$430 $164
2025 $2,666 $149 $61–$470 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,450 89 payments
  2. AstraZeneca Pharmaceuticals LP $1,267 43 payments
  3. Incyte Corporation $718 32 payments
  4. Astellas Pharma US Inc $701 24 payments
  5. Seattle Genetics, Inc. $511 17 payments
  6. Lilly USA, LLC $503 17 payments
  7. Amgen Inc. $464 17 payments
  8. Pfizer Inc. $446 20 payments
  9. Exelixis Inc. $431 20 payments
  10. Janssen Biotech, Inc. $397 22 payments
  11. Other $7,338 332 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,845 617 payments
  2. Education $1,382 16 payments
Products named General payments · program years 2021–2025
  1. KISQALI $467 32 payments
  2. IMFINZI $384 13 payments
  3. JAKAFI $327 18 payments
  4. ENHERTU Oncology $324 12 payments
  5. ENHERTU Oncology $316 14 payments
  6. Lenvima $303 15 payments
  7. MONJUVI $303 16 payments
  8. CABOMETYX $252 14 payments
  9. REBLOZYL $252 8 payments
  10. Fabhalta $249 17 payments
  11. Other $12,308 602 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

243

Median for Nurse Practitioner: 389

Drug cost

$14,171

Median for Nurse Practitioner: $21,885

Branded share of claims

22.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 21 $12,179
Anastrozole Generic 22 $495
Ondansetron Odt Ondansetron Brand 21 $364
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $194
Prednisone Generic 22 $148
Levothyroxine Sodium Generic 26 $130
Tramadol Hcl Generic 19 $129
Potassium Chloride Generic 24 $105
Allopurinol Generic 22 $105
Methylprednisolone Generic 16 $97

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 66 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $161
  • AstraZeneca Pharmaceuticals LP $66
$227 — —
Padcev
  • PFIZER INC. $125
  • Astellas Pharma US Inc $72
$197 — —
CABOMETYX
  • Exelixis Inc. $189
$189 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $148
  • Merck Sharp & Dohme Corporation $25
$174 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $159
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 66 with Patron

Records

633 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record